CTOs on the Move

Azurity

www.azurity.com

 
Azurity Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the needs of patients, especially children and the elderly, that require customized user-friendly drug formations. Our products have benefited millions of patients whose needs are not served by other commercially available therapies. AZURITY VALUES: COMPASSION - We put the needs of our patients and caregivers at the center of everything we do, including the decisions we make. QUALITY - We aim to provide our patients with the highest-quality, safe, and effective therapies for their needs. INNOVATION - We use the best science and manufacturing techniques to deliver cost-effective, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.azurity.com
  • 8 Cabot Road Suite 2000
    Woburn, MA USA 01801
  • Phone: 877.495.6858

Executives

Name Title Contact Details
Jordan Lilly
Chief of Staff & VP, Enterprise Project Management Office (EPMO) Profile
Robert Dullea
Vice President Cybersecurity and Information Technology Profile
Mark Sander
Chief Digital and Information Officer Profile

Similar Companies

Sagimet

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.

SGX Pharmaceuticals

SGX Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TubeWriter

TubeWriter is a company that provides direct labeling systems and services to the life sciences industry. Their solutions print on any laboratory tube, slide or plate, and offer superior durability of print at extreme temperatures, up to 90% reduction ...

Intersciences Inc

Intersciences Inc is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Milestone Pharmaceuticals

Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.